Co-Authors
This is a "connection" page, showing publications co-authored by AMY B HEIMBERGER and MICHAEL CURRAN.
Connection Strength
1.880
-
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J Clin Invest. 2024 Jun 17; 134(12).
Score: 0.249
-
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol. 2023 08 03; 25(8):1415-1427.
Score: 0.235
-
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res. 2022; 11:1010.
Score: 0.220
-
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology. 2022; 11(1):2062827.
Score: 0.214
-
Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clin Cancer Res. 2021 10 15; 27(20):5528-5535.
Score: 0.205
-
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
Score: 0.192
-
Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712.
Score: 0.189
-
Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194.
Score: 0.185
-
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).
Score: 0.140
-
Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res. 2021 08 01; 27(15):4325-4337.
Score: 0.050